Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Forte Biosciences, Inc. (FBRX)
USD43.33
+0.13 (+0.30%)
US NASDAQ Healthcare Biotechnology
Address
3060 Pegasus Park Drive 75247
Dallas, TX, US
Dallas, TX, US
CEO
Paul A. Wagner
Website
fortebiorx.com
IPO
2017-04-13
CIK 1419041 ISIN US34962G2084
Description
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.
News Sentiment (7d)
9 articles
- Forte Biosciences shares surge after positive phase 1b vitiligo results Proactive Investors
- Forte Biosciences shares surge after positive phase 1b vitiligo results Proactive Investors - Finance
- FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data Zacks Investment Research
- Forte Biosciences, Inc. (FBRX) Discusses Positive Results From FB102 Phase 1b Vitiligo Study and Mechanism of Action Transcript Seeking Alpha
- Forte Biosciences Skin Pigmentation Disorder Drug Shows Strong Efficacy, Safety In Early Study Benzinga
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Tocagen Inc. | TOCA | 2020-03-24 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD43.33
+0.13 (+0.30%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
346.9K
Beta
2.87
Float Shares
12.07M
Free Float %
86.9%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (6 ratings, all time)
Buy
Price Targets & DCF
Current price
43.33
Low
65.00
+50.0%
Consensus
65.00
+50.0%
Median
65.00
+50.0%
High
65.00
+50.0%
DCF (Unlevered)
0.47
-98.9%
DCF (Levered)
7.63
-82.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
65.00
+50.0%
|
| All Time | 1 |
65.00
+50.0%
|
Quality scores
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+61.3% ★ Q1'26: +9.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +556.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+4,947.4% Q1'26: +1,464.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2021 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 4 EPS Ana. |
Dec 2027 4 Rev. Ana. 4 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
41.0K
est: 43.0K (-4.7%)
|
18.04M
est: 18.02M (+0.1%)
|
—
est: 13.5K (-100.0%)
|
—
est: 9.6K (-100.0%)
|
—
|
—
|
9.00M
9.00M – 9.00M
|
22.50M
22.50M – 22.50M
+150.0% YoY
|
14.31M
14.31M – 14.31M
-36.4% YoY
|
32.44M
32.44M – 32.44M
+126.6% YoY
|
53.42M
53.42M – 53.42M
+64.7% YoY
|
| EBITDA |
-36.71M
|
-43.69M
|
-4.06M
est: -34.51M (+88.2%)
|
-21.45M
est: -26.77M (+19.9%)
|
-35.44M
|
-70.59M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-37.00M
|
-44.32M
|
-4.07M
est: -33.05M (+87.7%)
|
-21.49M
est: -25.47M (+15.7%)
|
-35.48M
|
-70.66M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-38.93M
est: -2.91B (+98.7%)
|
-48.96M
est: -2.31B (+97.9%)
|
-4.07M
est: -34.80M (+88.3%)
|
-21.71M
est: -27.03M (+19.7%)
|
-35.48M
est: -42.45M (+16.4%)
|
-69.38M
est: -649.69M (+89.3%)
|
-590.18M
-619.21M – -561.16M
+9.2% YoY
|
-609.61M
-818.82M – -400.40M
-3.3% YoY
|
-585.19M
-804.12M – -366.27M
+4.0% YoY
|
-873.25M
-873.25M – -873.25M
-49.2% YoY
|
-853.14M
-853.14M – -853.14M
+2.3% YoY
|
| SGA |
8.27M
|
12.81M
|
1.38M
|
7.63M
|
15.37M
|
12.41M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-997.50
est: -997.50 (+0.0%)
|
-915.18
est: -792.12 (-15.5%)
|
-48.25
est: -1,057.50 (+95.4%)
|
-38.85
est: -34.75 (-11.8%)
|
-12.17
est: -9.44 (-29.0%)
|
-4.71
est: -4.32 (-9.1%)
|
-4.01
-4.21 – -3.81
+7.1% YoY
|
-4.14
-5.56 – -2.72
-3.3% YoY
|
-4.17
-5.46 – -2.49
-0.7% YoY
|
-5.93
-5.93 – -5.93
-42.3% YoY
|
-5.80
-5.80 – -5.80
+2.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-30.74M
OE per share TTM
-13.48
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
24.4%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
71
Total invested
350.24M
Insider transactions (90d)
0
Beneficial owners (>5%)
50
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Daniel S. Short | 3.79M | 9.90% | — | 3.79M | — | — | IN | United States | 2023-08-10 | ↗ |
| 2 | David T. Kim | 3.79M | 9.90% | — | 3.79M | — | — | IN | United States | 2023-08-10 | ↗ |
| 3 | Edric C. Saito | 3.79M | 9.90% | — | 3.79M | — | — | IN | United States | 2023-08-10 | ↗ |
| 4 | Hannah E. Dunn | 3.79M | 9.90% | — | 3.79M | — | — | IN | United States | 2023-08-10 | ↗ |
| 5 | John R. Warren | 3.79M | 9.90% | — | 3.79M | — | — | IN | United States | 2023-08-10 | ↗ |
| 6 | Joshua J. Dapice | 3.79M | 9.90% | — | 3.79M | — | — | IN | United States | 2023-08-10 | ↗ |
| 7 | Michael G. Linn | 3.79M | 9.90% | — | 3.79M | — | — | IN | United States | 2023-08-10 | ↗ |
| 8 | Nicolas Giauque | 3.79M | 9.90% | — | 3.79M | — | — | IN | France | 2023-08-10 | ↗ |
| 9 | Rajiv A. Patel | 3.79M | 9.90% | — | 3.79M | — | — | IN | United States | 2023-08-10 | ↗ |
| 10 | Richard B. Fried | 3.79M | 9.90% | — | 3.79M | — | — | IN | United States | 2023-08-10 | ↗ |
| 11 | Varun N. Gehani | 3.79M | 9.90% | — | 3.79M | — | — | IN | United States | 2023-08-10 | ↗ |
| 12 | William Seybold | 3.79M | 9.90% | — | 3.79M | — | — | IN | United States | 2023-08-10 | ↗ |
| 13 | TYBOURNE CAPITAL MANAGEMENT (HK) LIMITED | 3.63M | 9.99% | — | 3.63M | — | 3.63M | FI | Hong Kong | 2024-02-14 | ↗ |
| 14 | TYBOURNE CAPITAL MANAGEMENT LIMITED | 3.63M | 9.99% | — | 3.63M | — | 3.63M | HC | Cayman Islands | 2024-02-14 | ↗ |
| 15 | TYBOURNE KESARI LIMITED | 3.63M | 9.99% | — | 3.63M | — | 3.63M | HC | Cayman Islands | 2024-02-14 | ↗ |
| 16 | TYBOURNE STRATEGIC OPPORTUNITIES GP II LIMITED | 3.63M | 9.99% | — | 3.63M | — | 3.63M | FI | Citizenship or Place of Organization. | 2024-02-14 | ↗ |
| 17 | VISWANATHAN KRISHNAN | 3.63M | 9.99% | — | 3.63M | — | 3.63M | HC, IN | United Kingdom | 2024-02-14 | ↗ |
| 18 | Joseph Edelman | 3.63M | 9.90% | — | 3.63M | — | 3.63M | IN | Delaware | 2023-09-08 | ↗ |
| 19 | Perceptive Advisors LLC | 3.63M | 9.90% | — | 3.63M | — | 3.63M | IA | Delaware | 2023-09-08 | ↗ |
| 20 | Perceptive Life Sciences Master Fund, Ltd. | 3.63M | 9.90% | — | 3.63M | — | 3.63M | CO | Delaware | 2023-09-08 | ↗ |
| 21 | Farallon Partners, L.L.C. | 3.48M | 9.10% | — | 3.48M | — | — | OO | Delaware | 2023-08-10 | ↗ |
| 22 | BVF Inc. | 2.98M | 8.20% | — | — | — | 2.98M | CO | — | 2023-08-10 | ↗ |
| 23 | BVF Partners L.P. | 2.98M | 8.20% | — | — | — | 2.98M | IA, PN | — | 2023-08-10 | ↗ |
| 24 | Mark N. Lampert | 2.98M | 8.20% | — | — | — | 2.98M | IN | — | 2023-08-10 | ↗ |
| 25 | BVF GP Holdings LLC | 2.80M | 7.70% | — | — | — | 2.80M | OO | — | 2023-08-10 | ↗ |
| 26 | 2. | 1.84M | 5.10% | 1.84M | — | 1.84M | — | HC | New York | 2023-09-12 | ↗ |
| 27 | Camac Capital, LLC | 1.58M | 4.30% | — | — | — | 1.58M | OO | — | 2023-08-23 | ↗ |
| 28 | Camac Fund, LP | 1.58M | 4.30% | — | — | — | 1.58M | PN | — | 2023-08-23 | ↗ |
| 29 | Camac Partners, LLC | 1.58M | 4.30% | — | — | — | 1.58M | OO | — | 2023-08-23 | ↗ |
| 30 | Eric Shahinian | 1.58M | 4.30% | — | — | — | 1.58M | IN | — | 2023-08-23 | ↗ |
| 31 | ATG Capital Management, LLC | 1.46M | 4.00% | — | — | — | 1.46M | OO | — | 2023-08-23 | ↗ |
| 32 | ATG Fund II LLC | 1.46M | 4.00% | — | — | — | 1.46M | OO | — | 2023-08-23 | ↗ |
| 33 | Gabriel Gliksberg | 1.46M | 4.00% | — | — | — | 1.46M | IN | — | 2023-08-23 | ↗ |
| 34 | Farallon Capital Offshore Investors II, L.P. | 1.44M | 3.90% | — | 1.44M | — | — | PN | Cayman Islands | 2023-08-10 | ↗ |
| 35 | Farallon Capital Institutional Partners, L.P. | 854.1K | 2.30% | — | 854.1K | — | — | PN | California | 2023-08-10 | ↗ |
| 36 | Farallon Capital F5 Master I, L.P. | 303.4K | 0.80% | — | 303.4K | — | — | PN | Cayman Islands | 2023-08-10 | ↗ |
| 37 | Farallon F5 (GP), L.L.C. | 303.4K | 0.80% | — | 303.4K | — | — | OO | Delaware | 2023-08-10 | ↗ |
| 38 | Farallon Capital Institutional Partners II, L.P. | 250.4K | 0.70% | — | 250.4K | — | — | PN | California | 2023-08-10 | ↗ |
| 39 | BVF Partners OS Ltd. | 141.7K | 1.00% | — | — | — | 141.7K | CO | — | 2023-08-10 | ↗ |
| 40 | Biotechnology Value Trading Fund OS LP | 141.7K | 1.00% | — | — | — | 141.7K | PN | — | 2023-08-10 | ↗ |
| 41 | Farallon Institutional (GP) V, L.L.C. | 110.6K | 0.30% | — | 110.6K | — | — | OO | Delaware | 2023-08-10 | ↗ |
| 42 | Four Crossings Institutional Partners V, L.P. | 110.6K | 0.30% | — | 110.6K | — | — | PN | Delaware | 2023-08-10 | ↗ |
| 43 | Farallon Capital Institutional Partners III, L.P. | 100.0K | 0.30% | — | 100.0K | — | — | PN | Delaware | 2023-08-10 | ↗ |
| 44 | Farallon Capital (AM) Investors, L.P. | 98.5K | 0.30% | — | 98.5K | — | — | PN | Delaware | 2023-08-10 | ↗ |
| 45 | Chris McIntyre | 39.8K | 1.00% | — | — | — | 39.8K | IN | — | 2023-08-23 | ↗ |
| 46 | McIntyre Capital GP, LLC | 39.8K | 1.00% | — | — | — | 39.8K | OO | — | 2023-08-23 | ↗ |
| 47 | McIntyre Capital Management GP, LLC | 39.8K | 1.00% | — | — | — | 39.8K | OO | — | 2023-08-23 | ↗ |
| 48 | McIntyre Capital Management, LP | 39.8K | 1.00% | — | — | — | 39.8K | PN | — | 2023-08-23 | ↗ |
| 49 | McIntyre Partnerships, LP | 39.8K | 1.00% | — | — | — | 39.8K | PN | — | 2023-08-23 | ↗ |
| 50 | Michael G. Hacke | — | 0.00% | — | — | — | — | IN | — | 2023-08-23 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
71
+11 vs prev Q
New positions
20
Closed positions
10
Increased
40
Reduced
21
Put/Call ratio
0.52
Calls held
44.4K
Puts held
22.9K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | FEDERATED HERMES, INC. | 1.77M +130.1K (+8.0%) | 48.15M +23.6M (+96.3%) | 9.92% -4.003 pp | 0.08% +0.037 pp | USD14.65 +86.1% | 3 qtrs — |
| 2 | FRED ALGER MANAGEMENT, LLC | 1.46M -175.1K (-10.7%) | 39.84M +15.3M (+62.3%) | 8.21% -5.720 pp | 0.16% +0.061 pp | USD17.70 +54.1% | 6 qtrs — |
| 3 | JANUS HENDERSON GROUP PLC | 1.43M +21.9K (+1.6%) | 39.16M +18.2M (+86.6%) | 8.01% -3.941 pp | 0.02% +0.008 pp | USD9.83 +177.4% | 4 qtrs — |
| 4 | ORBIMED ADVISORS LLC | 1.20M +— (+0.0%) | 32.64M +14.7M (+81.8%) | 6.73% -3.465 pp | 0.67% +0.246 pp | USD17.78 +53.4% | 5 qtrs — |
| 5 | AFFINITY ASSET ADVISORS, LLC | 989.5K +989.5K (+100.0%) | 26.98M +27.0M (+100.0%) | 5.56% +5.561 pp | 1.54% +1.538 pp | USD27.27 +0.0% | 1 qtrs NEW |
| 6 | VANGUARD GROUP INC | 582.3K +15.5K (+2.7%) | 15.88M +7.4M (+86.8%) | 3.27% -1.554 pp | 0.00% +0.000 pp | USD12.71 +114.6% | 6 qtrs — |
| 7 | POINT72 ASSET MANAGEMENT, L.P. | 487.3K +487.3K (+100.0%) | 13.29M +13.3M (+100.0%) | 2.74% +2.738 pp | 0.01% +0.015 pp | USD27.27 +0.0% | 1 qtrs NEW |
| 8 | CABLE CAR CAPITAL LLC | 400.0K -100.0K (-20.0%) | 10.91M +3.4M (+45.4%) | 2.25% -2.010 pp | 0.36% -2.852 pp | USD14.44 +88.9% | 6 qtrs — |
| 9 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 333.3K +— (+0.0%) | 9.09M +4.1M (+81.8%) | 1.87% -0.965 pp | 0.01% +0.006 pp | USD12.93 +110.9% | 3 qtrs — |
| 10 | WOODLINE PARTNERS LP | 332.0K +— (+0.0%) | 9.05M +4.1M (+81.8%) | 1.87% -0.961 pp | 0.04% +0.012 pp | USD18.94 +44.0% | 5 qtrs — |
| 11 | FMR LLC | 311.0K +66.6K (+27.2%) | 8.48M +4.8M (+131.3%) | 1.75% -0.333 pp | 0.00% +0.000 pp | USD17.63 +54.7% | 2 qtrs — |
| 12 | IKARIAN CAPITAL, LLC | 300.0K +— (+0.0%) | 8.18M +3.7M (+81.8%) | 1.69% -0.869 pp | 0.64% +0.184 pp | USD22.71 +20.1% | 5 qtrs — |
| 13 | MILLENNIUM MANAGEMENT LLC | 246.7K +126.9K (+105.9%) | 6.73M +4.9M (+274.3%) | 1.39% +0.366 pp | 0.00% +0.002 pp | USD20.40 +33.7% | 4 qtrs — |
| 14 | AWM INVESTMENT COMPANY, INC. | 236.8K -25.0K (-9.5%) | 6.46M +2.5M (+64.4%) | 1.33% -0.899 pp | 0.62% +0.256 pp | USD15.00 +81.8% | 2 qtrs — |
| 15 | JAIN GLOBAL LLC | 202.4K +202.4K (+100.0%) | 5.52M +5.5M (+100.0%) | 1.14% +1.138 pp | 0.03% +0.027 pp | USD27.27 +0.0% | 1 qtrs NEW |
| 16 | SPHERA FUNDS MANAGEMENT LTD. | 185.9K -288.4K (-60.8%) | 5.07M -2.0M (-28.8%) | 1.04% -2.994 pp | 0.98% -0.521 pp | USD12.93 +110.9% | 3 qtrs — |
| 17 | AMERIPRISE FINANCIAL INC | 153.0K +83.1K (+118.9%) | 4.17M +3.1M (+298.0%) | 0.86% +0.265 pp | 0.00% +0.001 pp | USD21.67 +25.8% | 2 qtrs — |
| 18 | GEODE CAPITAL MANAGEMENT, LLC | 124.6K +16.3K (+15.0%) | 3.40M +1.8M (+109.2%) | 0.70% -0.222 pp | 0.00% +0.000 pp | USD13.11 +108.0% | 6 qtrs — |
| 19 | MORGAN STANLEY | 70.5K +70.4K (+46,609.3%) | 1.92M +1.9M (+84,817.5%) | 0.40% +0.395 pp | 0.00% +0.000 pp | USD27.22 +0.2% | 6 qtrs — |
| 20 | GOLDMAN SACHS GROUP INC | 68.0K +68.0K (+100.0%) | 1.85M +1.9M (+100.0%) | 0.38% +0.382 pp | 0.00% +0.000 pp | USD27.27 +0.0% | 1 qtrs NEW |
| 21 | BLACKROCK, INC. | 64.5K +13.8K (+27.3%) | 1.76M +998.9K (+131.4%) | 0.36% -0.069 pp | 0.00% +0.000 pp | USD15.78 +72.8% | 6 qtrs — |
| 22 | J. GOLDMAN & CO LP | 60.8K +60.8K (+100.0%) | 1.66M +1.7M (+100.0%) | 0.34% +0.342 pp | 0.04% +0.044 pp | USD27.27 +0.0% | 1 qtrs NEW |
| 23 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 52.9K +52.9K (+100.0%) | 1.44M +1.4M (+100.0%) | 0.30% +0.297 pp | 0.00% +0.000 pp | USD27.27 +0.0% | 1 qtrs NEW |
| 24 | STATE STREET CORP | 50.7K +12.6K (+33.1%) | 1.38M +811.7K (+142.0%) | 0.29% -0.039 pp | 0.00% +0.000 pp | USD18.05 +51.1% | 2 qtrs — |
| 25 | 683 CAPITAL MANAGEMENT, LLC | 40.0K +40.0K (+100.0%) | 1.09M +1.1M (+100.0%) | 0.22% +0.225 pp | 0.05% +0.048 pp | USD27.27 +0.0% | 1 qtrs NEW |
| 26 | MARSHALL WACE, LLP | 36.3K +17.1K (+89.4%) | 989.8K +702.3K (+244.3%) | 0.20% +0.041 pp | 0.00% +0.001 pp | USD20.79 +31.2% | 2 qtrs — |
| 27 | QUBE RESEARCH & TECHNOLOGIES LTD | 32.2K +32.2K (+100.0%) | 877.7K +877.7K (+100.0%) | 0.18% +0.181 pp | 0.00% +0.001 pp | USD27.27 +0.0% | 1 qtrs NEW |
| 28 | TWO SIGMA INVESTMENTS, LP | 31.8K +31.8K (+100.0%) | 867.4K +867.4K (+100.0%) | 0.18% +0.179 pp | 0.00% +0.001 pp | USD27.27 +0.0% | 1 qtrs NEW |
| 29 | NORTHERN TRUST CORP | 25.4K +2.2K (+9.3%) | 693.8K +344.5K (+98.6%) | 0.14% -0.055 pp | 0.00% +0.000 pp | USD16.04 +70.0% | 2 qtrs — |
| 30 | UBS GROUP AG | 24.8K +23.3K (+1,491.3%) | 677.0K +653.6K (+2,793.0%) | 0.14% +0.126 pp | 0.00% +0.000 pp | USD26.50 +2.9% | 6 qtrs — |
| 31 | BARCLAYS PLC | 24.1K +24.1K (+2,411,000.0%) | 657.5K +657.5K (+10,958,350.0%) | 0.14% +0.136 pp | 0.00% +0.000 pp | USD27.27 +0.0% | 2 qtrs — |
| 32 | ENVESTNET ASSET MANAGEMENT INC | 19.5K -3.8K (-16.5%) | 531.7K +181.5K (+51.8%) | 0.11% -0.089 pp | 0.00% +0.000 pp | USD13.33 +104.6% | 3 qtrs — |
| 33 | QUEST PARTNERS LLC | 18.8K +6.5K (+53.0%) | 512.8K +328.4K (+178.1%) | 0.11% +0.001 pp | 0.03% +0.017 pp | USD17.05 +59.9% | 4 qtrs — |
| 34 | QUADRATURE CAPITAL LTD | 17.6K +17.6K (+100.0%) | 479.2K +479.2K (+100.0%) | 0.10% +0.099 pp | 0.00% +0.005 pp | USD27.27 +0.0% | 1 qtrs NEW |
| 35 | HUDSON BAY CAPITAL MANAGEMENT LP | 16.5K +16.5K (+100.0%) | 451.1K +451.1K (+100.0%) | 0.09% +0.093 pp | 0.00% +0.002 pp | USD27.27 +0.0% | 1 qtrs NEW |
| 36 | LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | 15.8K +15.8K (+100.0%) | 431.0K +431.0K (+100.0%) | 0.09% +0.089 pp | 0.03% +0.029 pp | USD27.27 +0.0% | 1 qtrs NEW |
| 37 | OMERS ADMINISTRATION CORP | 15.6K +15.6K (+100.0%) | 425.4K +425.4K (+100.0%) | 0.09% +0.088 pp | 0.00% +0.003 pp | USD27.27 +0.0% | 1 qtrs NEW |
| 38 | BNP PARIBAS ARBITRAGE, SNC | 15.5K +15.5K (+193,300.0%) | 421.9K +421.8K (+351,500.8%) | 0.09% +0.087 pp | 0.00% +0.000 pp | USD27.26 +0.0% | 6 qtrs — |
| 39 | TREXQUANT INVESTMENT LP | 12.9K +12.9K (+100.0%) | 352.2K +352.2K (+100.0%) | 0.07% +0.073 pp | 0.00% +0.003 pp | USD27.27 +0.0% | 1 qtrs NEW |
| 40 | ROYAL BANK OF CANADA | 12.0K +733.0 (+6.5%) | 327.0K +158.0K (+93.5%) | 0.07% -0.029 pp | 0.00% +0.000 pp | USD16.88 +61.6% | 5 qtrs — |
| 41 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 11.1K +11.1K (+100.0%) | 302.3K +302.3K (+100.0%) | 0.06% +0.062 pp | 0.00% +0.002 pp | USD27.27 +0.0% | 1 qtrs NEW |
| 42 | ALPS ADVISORS INC | 10.3K +10.3K (+100.0%) | 280.6K +280.6K (+100.0%) | 0.06% +0.058 pp | 0.00% +0.002 pp | USD27.27 +0.0% | 1 qtrs NEW |
| 43 | PERSISTENT ASSET PARTNERS LTD | 10.1K +10.1K (+100.0%) | 276.7K +276.7K (+100.0%) | 0.06% +0.057 pp | 0.12% +0.124 pp | USD27.27 +0.0% | 1 qtrs NEW |
| 44 | JANE STREET GROUP, LLC | 8.3K +8.3K (+100.0%) | 227.5K +227.5K (+100.0%) | 0.05% +0.047 pp | 0.00% +0.000 pp | USD27.27 +0.0% | 1 qtrs NEW |
| 45 | AMERICAN CENTURY COMPANIES INC | 8.1K +8.1K (+100.0%) | 220.5K +220.5K (+100.0%) | 0.05% +0.045 pp | 0.00% +0.000 pp | USD27.27 +0.0% | 1 qtrs NEW |
| 46 | SIMPLEX TRADING, LLC | 6.0K +6.0K (+100.0%) | 164.0K +164.0K (+100.0%) | 0.03% +0.034 pp | 0.00% +0.000 pp | USD27.27 +0.0% | 1 qtrs NEW |
| 47 | BANK OF AMERICA CORP /DE/ | 4.0K +814.0 (+25.8%) | 108.3K +60.9K (+128.7%) | 0.02% -0.005 pp | 0.00% +0.000 pp | USD17.42 +56.5% | 6 qtrs — |
| 48 | CITIGROUP INC | 1.3K +1.3K (+100.0%) | 34.9K +34.9K (+100.0%) | 0.01% +0.007 pp | 0.00% +0.000 pp | USD27.27 +0.0% | 1 qtrs NEW |
| 49 | GLOBAL RETIREMENT PARTNERS, LLC | 1.0K +1.0K (+100.0%) | 27.3K +27.3K (+100.0%) | 0.01% +0.006 pp | 0.00% +0.001 pp | USD27.27 +0.0% | 1 qtrs NEW |
| 50 | TOWER RESEARCH CAPITAL LLC (TRC) | 773.00 +611.0 (+377.2%) | 21.1K +18.7K (+767.5%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD24.70 +10.4% | 6 qtrs — |
| 51 | STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 553.00 +— (+0.0%) | 15.1K +6.8K (+81.8%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD15.00 +81.8% | 2 qtrs — |
| 52 | WELLS FARGO & COMPANY/MN | 502.00 +500.0 (+25,000.0%) | 13.7K +13.7K (+45,533.3%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD27.21 +0.2% | 3 qtrs — |
| 53 | GROUP ONE TRADING, L.P. | 204.00 +100.0 (+96.2%) | 5.6K +4.0K (+256.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD16.22 +68.1% | 6 qtrs — |
| 54 | COMERICA BANK | 150.00 +— (+0.0%) | 4.1K +1.8K (+81.8%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD13.14 +107.5% | 5 qtrs — |
| 55 | NATIONAL BANK OF CANADA /FI/ | 76.00 +76.0 (+100.0%) | 2.1K +2.1K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD27.26 +0.0% | 1 qtrs NEW |
| 56 | ASSETMARK, INC | 58.00 -23.0 (-28.4%) | 1.6K +367.0 (+30.2%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD15.00 +81.8% | 2 qtrs — |
| 57 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 28.00 +28.0 (+100.0%) | 764.00 +764.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD27.25 +0.1% | 1 qtrs NEW |
| 58 | SBI SECURITIES CO., LTD. | 12.00 -1.0 (-7.7%) | 327.00 +132.0 (+67.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD22.00 +24.0% | 5 qtrs — |
| 59 | REAP FINANCIAL GROUP, LLC | 3.00 +— (+0.0%) | 82.00 +37.0 (+82.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.33 +411.6% | 6 qtrs — |
| 60 | CITADEL ADVISORS LLC | — -15.6K (-100.0%) | — -234.5K (-100.0%) | 0.00% -0.133 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 61 | BVF INC/IL | — -65.4K (-100.0%) | — -980.3K (-100.0%) | 0.00% -0.556 pp | 0.00% -0.040 pp | USD— | 6 qtrs SOLD |
| 62 | MINK BROOK ASSET MANAGEMENT LLC | — -81.3K (-100.0%) | — -1.2M (-100.0%) | 0.00% -0.692 pp | 0.00% -0.822 pp | USD— | 3 qtrs SOLD |
| 63 | PRIVATE TRUST CO NA | — -274.0 (-100.0%) | — -4.1K (-100.0%) | 0.00% -0.002 pp | 0.00% 0.000 pp | USD— | 5 qtrs SOLD |
| 64 | DIMENSIONAL FUND ADVISORS LP | — -10.8K (-100.0%) | — -161.0K (-100.0%) | 0.00% -0.092 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 65 | RENAISSANCE TECHNOLOGIES LLC | — -16.2K (-100.0%) | — -243.0K (-100.0%) | 0.00% -0.138 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 50 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Alger 35 ETF ATFV | 1.20% | 1.30M | 0.55% |
| 2 | iShares Micro-Cap ETF IWC | 0.19% | 2.86M | 0.60% |
| 3 | Texas Capital Texas Equity Index ETF TXS | 0.12% | 40.7K | 0.49% |
| 4 | iShares Russell 2000 Growth ETF IWO | 0.05% | 8.01M | 0.24% |
| 5 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.05% | 494.2K | 0.20% |
| 6 | Invesco Russell 2000 Dynamic Multifactor ETF OMFS | 0.03% | 77.1K | 0.39% |
| 7 | State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc) R2US.L | 0.03% | 1.51M | 0.30% |
| 8 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.03% | 86.2K | 0.25% |
| 9 | Global X - Russell 2000 ETF RSSL | 0.03% | 396.0K | 0.08% |
| 10 | iShares Russell 2000 BuyWrite ETF IWMW | 0.03% | 14.7K | 0.39% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.50
Neutral
Ratio by volume
3.00
Bullish
Buys
6
Sells
4
Shares acquired
601.6K
Shares disposed
1.9K
Cash buys
—
Cash sales
—
Net activity
+599,682
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Wagner Paul A. | Director / Officer | M-Exempt | A | Common Stock | 1,250 | 0.00 | — | 84,428 | D | ↗ |
| 2026-04-01 | Riley Antony A | Officer | M-Exempt | A | Common Stock | 375 | 0.00 | — | 42,116 | D | ↗ |
| 2026-01-12 | Wagner Paul A. | Director / Officer | A-Award | A | Stock Option (right to buy) | 270,000 | 29.66 | 8.01M | 270,000 | D | ↗ |
| 2026-01-12 | Riley Antony A | Officer | A-Award | A | Restricted Stock Units | 60,000 | 0.00 | — | 60,000 | D | ↗ |
| 2026-01-01 | Wagner Paul A. | Director / Officer | M-Exempt | A | Common Stock | 1,250 | 0.00 | — | 83,342 | D | ↗ |
| 2026-01-01 | Riley Antony A | Officer | M-Exempt | A | Common Stock | 375 | 0.00 | — | 41,895 | D | ↗ |
| 2025-12-30 | Riley Antony A | Officer | P-Purchase | A | Common Stock | 9,680 | 26.33 | 254.8K | 41,520 | D | ↗ |
| 2025-10-01 | Wagner Paul A. | Director / Officer | M-Exempt | A | Common Stock | 1,250 | 0.00 | — | 82,190 | D | ↗ |
| 2025-10-01 | Riley Antony A | Officer | F-InKind | D | Common Stock | 134 | 14.52 | 1.9K | 31,840 | D | ↗ |
| 2025-07-01 | Wagner Paul A. | Director / Officer | M-Exempt | A | Common Stock | 1,250 | 0.00 | — | 81,038 | D | ↗ |
| 2025-07-01 | Riley Antony A | Officer | M-Exempt | A | Common Stock | 375 | 0.00 | — | 31,733 | D | ↗ |
| 2025-04-01 | Wagner Paul A. | Director / Officer | M-Exempt | A | Common Stock | 1,250 | 0.00 | — | 79,806 | D | ↗ |
| 2025-04-01 | Riley Antony A | Officer | M-Exempt | A | Common Stock | 375 | 0.00 | — | 31,372 | D | ↗ |
| 2025-03-20 | Wagner Paul A. | Director / Officer | A-Award | A | Stock Option (right to buy) | 920,000 | 7.54 | 6.94M | 920,000 | D | ↗ |
| 2025-03-20 | VINCENT RICHARD G | Director | A-Award | A | Stock Option (right to buy) | 31,000 | 7.54 | 233.7K | 31,000 | D | ↗ |
| 2025-03-20 | Riley Antony A | Officer | A-Award | A | Stock Option (right to buy) | 323,000 | 7.54 | 2.44M | 323,000 | D | ↗ |
| 2025-03-20 | Kornfeld Steven | Director | A-Award | A | Stock Option (right to buy) | 31,000 | 7.54 | 233.7K | 31,000 | D | ↗ |
| 2025-03-20 | Kapoor Shivpreet Singh | Director | A-Award | A | Stock Option (right to buy) | 31,000 | 7.54 | 233.7K | 31,000 | D | ↗ |
| 2025-03-20 | GRYSKA DAVID W | Director | A-Award | A | Stock Option (right to buy) | 31,000 | 7.54 | 233.7K | 31,000 | D | ↗ |
| 2025-03-20 | Doberstein Stephen K | Director | A-Award | A | Stock Option (right to buy) | 31,000 | 7.54 | 233.7K | 31,000 | D | ↗ |
| 2025-03-20 | Brun Scott C. | Director | A-Award | A | Stock Option (right to buy) | 31,000 | 7.54 | 233.7K | 31,000 | D | ↗ |
| 2025-03-19 | FINCK BARBARA K | Director | A-Award | A | Stock Option (right to buy) | 31,000 | 7.02 | 217.6K | 31,000 | D | ↗ |
| 2025-01-01 | Wagner Paul A. | Director / Officer | M-Exempt | D | Restricted Stock Units | 1,250 | 0.00 | — | 10,000 | D | ↗ |
| 2025-01-01 | Riley Antony A | Officer | M-Exempt | D | Restricted Stock Units | 375 | 0.00 | — | 3,000 | D | ↗ |
| 2024-11-21 | Riley Antony A | Officer | P-Purchase | A | Common Stock | 22,514 | 5.55 | 125.0K | 30,776 | D | ↗ |
| 2024-10-01 | Wagner Paul A. | Director / Officer | M-Exempt | A | Common Stock | 1,250 | 0.00 | — | 77,568 | D | ↗ |
| 2024-10-01 | Riley Antony A | Officer | M-Exempt | A | Common Stock | 375 | 0.00 | — | 8,395 | D | ↗ |
| 2024-09-17 | VINCENT RICHARD G | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-09-17 | Kapoor Shivpreet Singh | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-08-20 | Williams Donald Allen | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.34 | 17.2K | 50,000 | — | ↗ |
| 2024-08-20 | Kornfeld Steven | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.34 | 17.2K | 50,000 | — | ↗ |
| 2024-08-20 | GRYSKA DAVID W | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.34 | 17.2K | 50,000 | — | ↗ |
| 2024-08-20 | FINCK BARBARA K | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.34 | 17.2K | 50,000 | — | ↗ |
| 2024-08-20 | Eichenfield Lawrence | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.34 | 17.2K | 50,000 | — | ↗ |
| 2024-08-20 | Doberstein Stephen K | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.34 | 17.2K | 50,000 | — | ↗ |
| 2024-08-20 | Brun Scott C. | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.34 | 17.2K | 50,000 | — | ↗ |
| 2024-07-01 | Wagner Paul A. | Director / Officer | M-Exempt | A | Common Stock | 31,250 | 0.00 | — | 1,910,424 | — | ↗ |
| 2024-07-01 | Riley Antony A | Officer | M-Exempt | A | Common Stock | 9,375 | 0.00 | — | 203,849 | — | ↗ |
| 2024-04-01 | Wagner Paul A. | Director / Officer | F-InKind | D | Common Stock | 2,453 | 0.71 | 1.7K | 1,879,174 | — | ↗ |
| 2024-04-01 | Riley Antony A | Officer | M-Exempt | D | Restricted Stock Units | 9,375 | 0.00 | — | 103,125 | — | ↗ |
| 2024-03-21 | Wagner Paul A. | Director / Officer | A-Award | A | Stock Option (right to buy) | 1,100,000 | 0.69 | 759.0K | 1,100,000 | — | ↗ |
| 2024-03-21 | Riley Antony A | Officer | A-Award | A | Stock Option (right to buy) | 350,000 | 0.69 | 241.5K | 350,000 | — | ↗ |
| 2024-03-21 | FINCK BARBARA K | Director | A-Award | A | Stock Option (right to buy) | 175,000 | 0.69 | 120.8K | 175,000 | — | ↗ |
| 2024-01-01 | Wagner Paul A. | Director / Officer | M-Exempt | D | Restricted Stock Units | 31,250 | 0.00 | — | 375,000 | — | ↗ |
| 2024-01-01 | Riley Antony A | Officer | F-InKind | D | Common Stock | 3,841 | 0.82 | 3.2K | 188,444 | — | ↗ |
| 2024-01-01 | Chen Hubert C | Officer | M-Exempt | D | Restricted Stock Units | 7,500 | 0.00 | — | 90,000 | — | ↗ |
| 2023-12-18 | Wagner Paul A. | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 0.75 | 7.5K | 1,823,236 | — | ↗ |
| 2023-12-14 | Wagner Paul A. | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 0.72 | 7.2K | 1,813,236 | — | ↗ |
| 2023-12-13 | Wagner Paul A. | Director / Officer | P-Purchase | A | Common Stock | 10,520 | 0.70 | 7.4K | 1,803,236 | — | ↗ |
| 2023-12-12 | Wagner Paul A. | Director / Officer | P-Purchase | A | Common Stock | 4,776 | 0.65 | 3.1K | 1,792,716 | — | ↗ |
| 2023-12-11 | Wagner Paul A. | Director / Officer | P-Purchase | A | Common Stock | 25,000 | 0.65 | 16.2K | 1,787,940 | — | ↗ |
| 2023-12-08 | Wagner Paul A. | Director / Officer | P-Purchase | A | Common Stock | 15,000 | 0.62 | 9.3K | 1,762,940 | — | ↗ |
| 2023-12-07 | Wagner Paul A. | Director / Officer | P-Purchase | A | Common Stock | 36,203 | 0.58 | 21.2K | 1,747,940 | — | ↗ |
| 2023-11-22 | Wagner Paul A. | Director / Officer | P-Purchase | A | Common Stock | 400 | 0.43 | 172.00 | 1,711,737 | — | ↗ |
| 2023-11-20 | Wagner Paul A. | Director / Officer | P-Purchase | A | Common Stock | 100 | 0.43 | 42.51 | 1,711,337 | — | ↗ |
| 2023-10-01 | Wagner Paul A. | Director / Officer | F-InKind | D | Common Stock | 2,453 | 0.66 | 1.6K | 1,704,371 | — | ↗ |
| 2023-10-01 | Riley Antony A | Officer | F-InKind | D | Common Stock | 3,241 | 0.66 | 2.1K | 182,910 | — | ↗ |
| 2023-10-01 | Chen Hubert C | Officer | M-Exempt | A | Common Stock | 7,500 | 0.00 | — | 91,571 | — | ↗ |
| 2023-09-19 | Williams Donald Allen | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.80 | 20.0K | 25,000 | — | ↗ |
| 2023-09-19 | Kornfeld Steven | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.80 | 20.0K | 25,000 | — | ↗ |
| 2023-09-19 | GRYSKA DAVID W | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.80 | 20.0K | 25,000 | — | ↗ |
| 2023-09-19 | FINCK BARBARA K | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.80 | 20.0K | 25,000 | — | ↗ |
| 2023-09-19 | Eichenfield Lawrence | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.80 | 20.0K | 25,000 | — | ↗ |
| 2023-09-19 | Doberstein Stephen K | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.80 | 20.0K | 25,000 | — | ↗ |
| 2023-09-19 | Brun Scott C. | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.80 | 20.0K | 25,000 | — | ↗ |
| 2023-07-31 | Williams Donald Allen | Director | A-Award | A | Common Stock | 59,405 | 1.01 | 60.0K | 59,405 | — | ↗ |
| 2023-07-31 | Wagner Paul A. | Director / Officer | A-Award | A | Common Stock | 247,524 | 1.01 | 250.0K | 1,675,574 | — | ↗ |
| 2023-07-31 | Riley Antony A | Officer | A-Award | A | Common Stock | 148,514 | 1.01 | 150.0K | 176,776 | — | ↗ |
| 2023-07-31 | Kornfeld Steven | Director | A-Award | A | Common Stock | 99,009 | 1.01 | 100.0K | 99,009 | — | ↗ |
| 2023-07-31 | GRYSKA DAVID W | Director | A-Award | A | Common Stock | 148,514 | 1.01 | 150.0K | 148,514 | — | ↗ |
| 2023-07-31 | Chen Hubert C | Officer | A-Award | A | Common Stock | 74,257 | 1.01 | 75.0K | 84,071 | — | ↗ |
| 2023-07-01 | Wagner Paul A. | Director / Officer | M-Exempt | D | Restricted Stock Units | 31,250 | 0.00 | — | 437,500 | — | ↗ |
| 2023-07-01 | Riley Antony A | Officer | M-Exempt | D | Restricted Stock Units | 9,375 | 0.00 | — | 131,250 | — | ↗ |
| 2023-07-01 | Chen Hubert C | Officer | M-Exempt | A | Common Stock | 7,500 | 0.00 | — | 12,407 | — | ↗ |
| 2023-04-01 | Wagner Paul A. | Director / Officer | M-Exempt | D | Restricted Stock Units | 31,250 | 0.00 | — | 468,750 | — | ↗ |
| 2023-04-01 | Riley Antony A | Officer | M-Exempt | A | Common Stock | 9,375 | 0.00 | — | 21,869 | — | ↗ |
| 2023-04-01 | Chen Hubert C | Officer | M-Exempt | A | Common Stock | 7,500 | 0.00 | — | 7,500 | — | ↗ |
| 2023-03-23 | Wagner Paul A. | Director / Officer | A-Award | A | Restricted Stock Units | 500,000 | 0.00 | — | 500,000 | — | ↗ |
| 2023-02-25 | Riley Antony A | Officer | A-Award | A | Restricted Stock Units | 150,000 | 0.00 | — | 150,000 | — | ↗ |
| 2023-02-25 | Chen Hubert C | Officer | A-Award | A | Restricted Stock Units | 120,000 | 0.00 | — | 120,000 | — | ↗ |
| 2023-01-10 | GRYSKA DAVID W | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-16 | Wagner Paul A. | Officer | P-Purchase | A | Common Stock | 44,024 | 1.07 | 47.0K | 1,379,049 | — | ↗ |
| 2022-12-15 | Wagner Paul A. | Officer | P-Purchase | A | Common Stock | 55,976 | 1.03 | 57.7K | 1,335,025 | — | ↗ |
| 2022-11-10 | Brun Scott C. | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-06-07 | Chen Hubert C | Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 0.00 | — | 250,000 | — | ↗ |
| 2022-06-01 | Williams Donald Allen | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-01 | Walker Patricia S | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-01 | Kornfeld Steven | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-01 | FINCK BARBARA K | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.27 | 31.8K | 25,000 | — | ↗ |
| 2022-06-01 | Eichenfield Lawrence | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-01 | Doberstein Stephen K | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-05-12 | Wagner Paul A. | Director / Officer | D-Return | D | Stock Option (right to buy) | 40,000 | 39.66 | 1.59M | 135,000 | — | ↗ |
| 2022-05-12 | Doberstein Stephen K | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 1.18 | 59.0K | 50,000 | — | ↗ |
| 2022-03-16 | FINCK BARBARA K | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-02-23 | Williams Donald Allen | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.27 | 31.8K | 25,000 | — | ↗ |
| 2022-02-23 | Walker Patricia S | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.27 | 31.8K | 25,000 | — | ↗ |
| 2022-02-23 | Kornfeld Steven | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.27 | 31.8K | 25,000 | — | ↗ |
| 2022-02-23 | Eichenfield Lawrence | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.27 | 31.8K | 25,000 | — | ↗ |
| 2022-01-17 | Wagner Paul A. | Director / Officer | A-Award | A | Stock Option (right to buy) | 300,000 | 1.72 | 516.0K | 300,000 | — | ↗ |
| 2022-01-17 | Riley Antony A | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 1.72 | 129.0K | 75,000 | — | ↗ |
| 2021-09-07 | Wagner Paul A. | Director / Officer | S-Sale | D | Common Stock | 1,000,000 | 4.35 | 4.35M | 1,279,049 | — | ↗ |
| 2021-09-07 | Riley Antony A | Officer | S-Sale | D | Common Stock | 21,484 | 4.24 | 91.1K | 14,581 | — | ↗ |
| 2021-05-28 | Williams Donald Allen | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 35.54 | 710.8K | 20,000 | — | ↗ |
| 2021-05-28 | Walker Patricia S | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 35.54 | 710.8K | 20,000 | — | ↗ |
| 2021-05-28 | Kornfeld Steven | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 35.54 | 710.8K | 20,000 | — | ↗ |
| 2021-05-28 | Eichenfield Lawrence | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 35.54 | 710.8K | 20,000 | — | ↗ |
| 2021-04-09 | Wagner Paul A. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 175,000 | 39.66 | 6.94M | 175,000 | — | ↗ |
| 2021-04-09 | Riley Antony A | Officer | A-Award | A | Stock Option (right to buy) | 42,500 | 39.66 | 1.69M | 42,500 | — | ↗ |
| 2021-01-13 | DARCY THOMAS E | Director | M-Exempt | A | Common Stock | 500 | 9.59 | 4.8K | 2,358 | — | ↗ |
| 2020-06-30 | Riley Antony A | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 14.58 | 1.09M | 75,000 | — | ↗ |
| 2020-06-29 | Riley Antony A | Officer | P-Purchase | A | Common Stock | 2,000 | 14.11 | 28.2K | 36,065 | — | ↗ |
| 2020-06-26 | Riley Antony A | Officer | P-Purchase | A | Common Stock | 4,700 | 14.52 | 68.2K | 34,065 | — | ↗ |
| 2020-06-25 | Wagner Paul A. | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 7,000 | 14.48 | 101.4K | 2,279,049 | — | ↗ |
| 2020-06-15 | Williams Donald Allen | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-15 | Walker Patricia S | Director | — | D | Stock Option (right to buy) | 5,270 | 1.19 | 6.3K | 0 | — | ↗ |
| 2020-06-15 | Wagner Paul A. | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 2,272,049 | — | ↗ |
| 2020-06-15 | Riley Antony A | Officer | — | D | Stock Option (right to buy) | 10,541 | 1.24 | 13.1K | 0 | — | ↗ |
| 2020-06-15 | Kornfeld Steven | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-15 | Eichenfield Lawrence | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 18.90 | 567.0K | 30,000 | — | ↗ |
| 2020-06-15 | DARCY THOMAS E | Director | A-Award | A | Common Stock | 1,858 | 0.00 | — | 1,858 | — | ↗ |
| 2020-04-14 | Oliveira Steven Michael | 10% Owner | P-Purchase | A | Common Stock | 74,301 | 1.19 | 88.4K | 2,873,450 | — | ↗ |
| 2020-03-02 | Oliveira Steven Michael | 10% Owner | P-Purchase | A | Common Stock | 65,149 | 1.35 | 87.8K | 2,799,149 | — | ↗ |
| 2020-02-26 | GRUBER HARRY E | Director / Officer | A-Award | A | Common Stock | 13,941 | 0.00 | — | 23,685 | — | ↗ |
| 2020-02-20 | Oliveira Steven Michael | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 2,734,000 | — | ↗ |
| 2019-10-04 | SCHIMMEL PAUL | Director | A-Award | A | Stock Option (right to buy) | 7,500 | 0.64 | 4.8K | 7,500 | — | ↗ |
| 2019-10-04 | Parkinson David Ross | Director | A-Award | A | Stock Option (right to buy) | 7,500 | 0.64 | 4.8K | 7,500 | — | ↗ |
| 2019-10-04 | Kunkel Lori Anne | Director | A-Award | A | Stock Option (right to buy) | 7,500 | 0.64 | 4.8K | 7,500 | — | ↗ |
| 2019-10-04 | Kabbinavar Fairooz | Officer | A-Award | A | Employee Stock Option (right to buy) | 20,000 | 0.64 | 12.8K | 20,000 | — | ↗ |
| 2019-10-04 | Jolly Douglas | Officer | A-Award | A | Employee Stock Option (right to buy) | 12,500 | 0.64 | 8.0K | 12,500 | — | ↗ |
| 2019-10-04 | Hasnain Faheem | Director | A-Award | A | Stock Option (right to buy) | 7,500 | 0.64 | 4.8K | 7,500 | — | ↗ |
| 2019-10-04 | GRUBER HARRY E | Director / Officer | A-Award | A | Stock Option (right to buy) | 7,500 | 0.64 | 4.8K | 7,500 | — | ↗ |
| 2019-10-04 | FOLETTA MARK G | Officer | A-Award | A | Employee Stock Option (right to buy) | 30,000 | 0.64 | 19.2K | 30,000 | — | ↗ |
| 2019-10-04 | Duvall Martin J | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 0.64 | 32.0K | 50,000 | — | ↗ |
| 2019-10-04 | DARCY THOMAS E | Director | A-Award | A | Stock Option (right to buy) | 7,500 | 0.64 | 4.8K | 7,500 | — | ↗ |
| 2019-10-04 | BERGER FRANKLIN M | Director | A-Award | A | Stock Option (right to buy) | 7,500 | 0.64 | 4.8K | 7,500 | — | ↗ |
| 2019-05-30 | Hasnain Faheem | Director | P-Purchase | A | Common Stock | 250 | 5.15 | 1.3K | 245,857 | — | ↗ |
| 2019-05-29 | SCHIMMEL PAUL | Director | A-Award | A | Stock option (right to buy) | 20,000 | 4.22 | 84.4K | 20,000 | — | ↗ |
| 2019-05-29 | Parkinson David Ross | Director | A-Award | A | Stock option (right to buy) | 20,000 | 4.22 | 84.4K | 20,000 | — | ↗ |
| 2019-05-29 | Kunkel Lori Anne | Director | A-Award | A | Stock option (right to buy) | 20,000 | 4.22 | 84.4K | 20,000 | — | ↗ |
| 2019-05-29 | Hasnain Faheem | Director | A-Award | A | Stock option (right to buy) | 20,000 | 4.22 | 84.4K | 20,000 | — | ↗ |
| 2019-05-29 | DARCY THOMAS E | Director | A-Award | A | Stock option (right to buy) | 20,000 | 4.22 | 84.4K | 20,000 | — | ↗ |
| 2019-05-29 | BERGER FRANKLIN M | Director | A-Award | A | Stock option (right to buy) | 20,000 | 4.22 | 84.4K | 20,000 | — | ↗ |
| 2019-05-28 | FOLETTA MARK G | Officer | P-Purchase | A | Common Stock | 5,000 | 4.30 | 21.5K | 15,042 | — | ↗ |
| 2019-05-28 | Duvall Martin J | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 4.34 | 21.7K | 13,605 | — | ↗ |
| 2019-05-24 | GRUBER HARRY E | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 4.56 | 22.8K | 9,744 | — | ↗ |
| 2019-04-15 | Kabbinavar Fairooz | Officer | A-Award | A | Employee Stock Option (right to buy) | 100,000 | 9.94 | 994.0K | 100,000 | — | ↗ |
| 2019-03-01 | Jolly Douglas | Officer | A-Award | A | Employee Stock Option (right to buy) | 25,000 | 11.00 | 275.0K | 25,000 | — | ↗ |
| 2019-03-01 | FOLETTA MARK G | Officer | A-Award | A | Employee Stock Option (right to buy) | 75,000 | 11.00 | 825.0K | 75,000 | — | ↗ |
| 2019-03-01 | Duvall Martin J | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 160,000 | 11.00 | 1.76M | 160,000 | — | ↗ |
| 2019-01-11 | Kunkel Lori Anne | Officer | A-Award | A | Stock option (right to buy) | 35,000 | 9.27 | 324.5K | 35,000 | — | ↗ |
| 2018-12-10 | Jolly Douglas | Officer | A-Award | A | Common Stock | 732 | 8.19 | 6.0K | 393,478 | — | ↗ |
| 2018-06-21 | SCHIMMEL PAUL | Director | A-Award | A | Stock option (right to buy) | 20,000 | 8.98 | 179.6K | 20,000 | — | ↗ |
| 2018-06-21 | Parkinson David Ross | Director | A-Award | A | Stock option (right to buy) | 20,000 | 8.98 | 179.6K | 20,000 | — | ↗ |
| 2018-06-21 | Kunkel Lori Anne | Director | A-Award | A | Stock option (right to buy) | 20,000 | 8.98 | 179.6K | 20,000 | — | ↗ |
| 2018-06-21 | Hasnain Faheem | Director | A-Award | A | Stock option (right to buy) | 20,000 | 8.98 | 179.6K | 20,000 | — | ↗ |
| 2018-06-21 | DARCY THOMAS E | Director | A-Award | A | Stock option (right to buy) | 20,000 | 8.98 | 179.6K | 20,000 | — | ↗ |
| 2018-06-21 | BERGER FRANKLIN M | Director | A-Award | A | Stock option (right to buy) | 20,000 | 8.98 | 179.6K | 20,000 | — | ↗ |
| 2018-06-08 | Jolly Douglas | Officer | A-Award | A | Common Stock | 703 | 8.19 | 5.8K | 392,746 | — | ↗ |
| 2018-03-01 | Jolly Douglas | Officer | A-Award | A | Employee Stock Option (right to buy) | 25,000 | 11.19 | 279.8K | 25,000 | — | ↗ |
| 2018-03-01 | FOLETTA MARK G | Officer | A-Award | A | Employee Stock Option (right to buy) | 85,000 | 11.19 | 951.2K | 85,000 | — | ↗ |
| 2018-03-01 | Duvall Martin J | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 150,000 | 11.19 | 1.68M | 150,000 | — | ↗ |
| 2018-03-01 | Das Asha | Officer | A-Award | A | Employee Stock Option (right to buy) | 70,000 | 11.19 | 783.3K | 70,000 | — | ↗ |
| 2017-12-08 | Jolly Douglas | Officer | J-Other | A | Common Stock | 739 | 8.50 | 6.3K | 392,043 | — | ↗ |
| 2017-12-08 | GRUBER HARRY E | Director / Officer | J-Other | A | Common Stock | 2,500 | 8.50 | 21.3K | 2,500 | — | ↗ |
| 2017-12-08 | FOLETTA MARK G | Officer | J-Other | A | Common Stock | 2,500 | 8.50 | 21.3K | 7,500 | — | ↗ |
| 2017-12-08 | Duvall Martin J | Director / Officer | J-Other | A | Common Stock | 2,500 | 8.50 | 21.3K | 6,071 | — | ↗ |
| 2017-12-08 | Das Asha | Officer | J-Other | A | Common Stock | 2,500 | 8.50 | 21.3K | 5,000 | — | ↗ |
| 2017-05-26 | Jolly Douglas | Officer | A-Award | A | Employee Stock Option (right to buy) | 35,000 | 16.32 | 571.2K | 35,000 | — | ↗ |
| 2017-05-26 | GRUBER HARRY E | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 40,000 | 16.32 | 652.8K | 40,000 | — | ↗ |
| 2017-05-26 | FOLETTA MARK G | Officer | A-Award | A | Employee Stock Option (right to buy) | 85,000 | 16.32 | 1.39M | 85,000 | — | ↗ |
| 2017-05-26 | Duvall Martin J | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 285,000 | 16.32 | 4.65M | 285,000 | — | ↗ |
| 2017-05-26 | Das Asha | Officer | A-Award | A | Employee Stock Option (right to buy) | 130,000 | 16.32 | 2.12M | 130,000 | — | ↗ |
| 2017-04-19 | SCHIMMEL PAUL | Director | C-Conversion | D | Series H Preferred Stock | 161,906 | 0.00 | — | 0 | — | ↗ |
| 2017-04-19 | Hasnain Faheem | Director | J-Other | A | Common Stock | 102,857 | 10.00 | 1.03M | 102,857 | — | ↗ |
| 2017-04-19 | GRUBER HARRY E | Director / Officer | P-Purchase | A | Common Stock | 25,000 | 10.00 | 250.0K | 417,753 | — | ↗ |
| 2017-04-19 | FOLETTA MARK G | Officer | P-Purchase | A | Common Stock | 5,000 | 10.00 | 50.0K | 5,000 | — | ↗ |
| 2017-04-19 | Duvall Martin J | Director / Officer | J-Other | A | Common Stock | 3,571 | 10.00 | 35.7K | 3,571 | — | ↗ |
| 2017-04-19 | Das Asha | Officer | P-Purchase | A | Common Stock | 2,500 | 10.00 | 25.0K | 2,500 | — | ↗ |
| 2017-04-19 | BERGER FRANKLIN M | Director | J-Other | A | Common Stock | 25,335 | 10.00 | 253.4K | 25,335 | — | ↗ |
| 2017-04-15 | BERMAN DENNIS N | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-04-12 | SCHIMMEL PAUL | Director | A-Award | A | Stock Option (right to buy) | 4,528 | 10.00 | 45.3K | 4,528 | — | ↗ |
| 2017-04-12 | Parkinson David Ross | Director | A-Award | A | Stock Option (right to buy) | 4,528 | 10.00 | 45.3K | 4,528 | — | ↗ |
| 2017-04-12 | Kunkel Lori Anne | Director | — | D | Stock Option (right to buy) | 2,644 | 14.98 | 39.6K | 0 | — | ↗ |
| 2017-04-12 | Jolly Douglas | Officer | — | D | Employee Stock Option (right to buy) | 57,971 | 3.94 | 228.4K | 0 | — | ↗ |
| 2017-04-12 | Hasnain Faheem | Director | — | D | Stock Option (right to buy) | 43,478 | 11.60 | 504.3K | 0 | — | ↗ |
| 2017-04-12 | GRUBER HARRY E | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 392,753 | — | ↗ |
| 2017-04-12 | FOLETTA MARK G | Officer | — | D | Employee Stock Option (right to buy) | 69,636 | 15.12 | 1.05M | 0 | — | ↗ |
| 2017-04-12 | Duvall Martin J | Director / Officer | — | D | Employee Stock Option (right to buy) | 308,706 | 16.56 | 5.11M | 0 | — | ↗ |
| 2017-04-12 | Das Asha | Officer | — | D | Employee Stock Option (right to buy) | 2,173 | 14.98 | 32.6K | 0 | — | ↗ |
| 2017-04-12 | DARCY THOMAS E | Director / Officer | — | D | Employee Stock Option (right to buy) | 66,666 | 3.94 | 262.7K | 0 | — | ↗ |
| 2017-04-12 | BERMAN DENNIS N | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 246,376 | — | ↗ |
| 2017-04-12 | BERGER FRANKLIN M | Director | — | D | Stock Option (right to buy) | 28,985 | 11.60 | 336.2K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
13.89M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Paul A. Wagner, Ph.D. Chairman, President and Chief Executive Officer | 670.1K | — | — | 5.95M | 737.1K | — | 7.36M | 80.88% | ↗ |
| 2 | 2025 | Antony A. Riley Chief Financial Officer | 452.1K | — | — | 2.09M | 180.8K | — | 2.72M | 76.75% | ↗ |
| 3 | 2024 | Paul A. Wagner, Ph.D. Chairman, President and Chief Executive Officer | 644.3K | — | 643.6K | — | 386.6K | — | 1.67M | 38.44% | ↗ |
| 4 | 2024 | Antony Riley Chief Financial Officer | 434.7K | — | 204.8K | — | 217.4K | — | 856.9K | 23.90% | ↗ |
| 5 | 2024 | Antony A. Riley Chief Financial Officer | 434.7K | — | 204.8K | — | 217.4K | — | 856.9K | 23.90% | ↗ |
| 6 | 2024 | Hubert C. Chen, M.D. Former President and Chief Scientific Officer | 50.3K | — | — | — | 180.0K | — | 230.3K | 0.00% | ↗ |
| 7 | 2023 | Paul A. Wagner, Ph.D. Chairman, President and Chief Executive Officer | 619.5K | — | 490.0K | — | 340.7K | — | 1.45M | 33.79% | ↗ |
| 8 | 2023 | Antony Riley Chief Financial Officer | 418.0K | — | 154.5K | — | 150.5K | — | 723.0K | 21.37% | ↗ |
| 9 | 2023 | Hubert C. Chen, M.D. Former President and Chief Scientific Officer | 450.0K | — | 123.6K | — | — | — | 573.6K | 21.55% | ↗ |
| 10 | 2022 | Paul A. Wagner, Ph.D. Chairman, President and Chief Executive Officer | 590.0K | 324.5K | — | 313.1K | — | — | 1.23M | 25.51% | ↗ |
| 11 | 2022 | Antony Riley Chief Financial Officer | 380.0K | 152.0K | — | 78.3K | — | — | 610.3K | 12.83% | ↗ |
| 12 | 2022 | Hubert C. Chen, M.D. Former President and Chief Scientific Officer | 255.7K | 102.6K | — | 211.6K | — | — | 569.9K | 37.13% | ↗ |
| 13 | 2021 | Paul A. Wagner, Ph.D. Chairman and Chief Executive Officer | 590.0K | 162.5K | 295.0K | 4.37M | — | — | 5.42M | 86.11% | ↗ |
| 14 | 2021 | Antony Riley Chief Financial Officer | 380.0K | 76.0K | 250.0K | 1.06M | — | — | 1.77M | 74.19% | ↗ |
| 15 | 2020 | Marty J. Duvall Chief Executive Officer | 233.7K | — | 76.9K | — | — | 862.9K | 1.17M | 6.55% | ↗ |
| 16 | 2020 | Antony Riley Chief Financial Officer | 264.1K | 110.0K | — | 682.2K | — | — | 1.06M | 64.58% | ↗ |
| 17 | 2020 | Paul A. Wagner, Ph.D. Chairman and Chief Executive Officer | 452.9K | 324.0K | — | — | — | — | 776.9K | 0.00% | ↗ |
| 18 | 2020 | Mark Foletta Executive Vice President and Chief Financial Officer | 180.0K | — | 51.3K | — | — | 458.7K | 690.0K | 7.43% | ↗ |
| 19 | 2019 | Marty J. Duvall Chief Executive Officer | 515.0K | — | — | 1.26M | — | 474.00 | 1.77M | 70.92% | ↗ |
| 20 | 2019 | Mark Foletta Executive Vice President and Chief Financial Officer | 388.3K | — | — | 592.4K | — | 360.00 | 981.1K | 60.38% | ↗ |
| 21 | 2019 | Paul A. Wagner, Ph.D. Chairman and Chief Executive Officer | 350.0K | 175.0K | — | — | — | — | 525.0K | 0.00% | ↗ |
| 22 | 2018 | Martin J. Duvall Chief Executive Officer | 511.2K | — | — | 1.24M | 270.9K | 560.00 | 2.02M | 61.25% | ↗ |
| 23 | 2018 | Mark Foletta Executive Vice President and Chief Financial Officer | 379.0K | — | — | 701.1K | 160.7K | 426.00 | 1.24M | 56.48% | ↗ |
| 24 | 2018 | Asha Das, M.D. Former Senior Vice President and Chief Medical Officer | 341.8K | — | — | 577.3K | — | 427.00 | 919.6K | 62.78% | ↗ |
| 25 | 2018 | Douglas Jolly, Ph.D. Executive Vice President, Research and Pharmaceutical Development | 297.0K | — | — | 206.2K | 119.7K | 150.00 | 623.1K | 33.09% | ↗ |
| 26 | 2017 | Martin J. Duvall Chief Executive Officer | 446.2K | — | — | 3.63M | 265.5K | 59.9K | 4.40M | 82.45% | ↗ |
| 27 | 2017 | Mark Foletta Executive Vice President and Chief Financial Officer | 304.8K | — | — | 1.70M | 145.1K | 563.00 | 2.15M | 79.02% | ↗ |
| 28 | 2017 | Asha Das, M.D. Senior Vice President and Chief Medical Officer | 346.7K | — | — | 1.56M | 140.2K | 750.00 | 2.05M | 76.18% | ↗ |
| 29 | 2017 | Asha Das, M.D. Former Senior Vice President and Chief Medical Officer | 346.7K | — | — | 1.56M | 140.2K | 750.00 | 2.05M | 76.18% | ↗ |
| 30 | 2017 | Douglas Jolly, Ph.D. Executive Vice President, Research and Pharmaceutical Development | 267.0K | — | — | 503.9K | 106.8K | 489.00 | 878.1K | 57.39% | ↗ |
| 31 | 2016 | Martin J. Duvall Chief Executive Officer | 67.7K | — | — | 3.03M | 24.0K | 18.5K | 3.14M | 96.50% | ↗ |
| 32 | 2016 | Asha Das, M.D. Senior Vice President and Chief Medical Officer | 313.7K | — | — | 20.5K | 50.0K | 7.4K | 391.5K | 5.23% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Paul A. Wagner | Chief Executive Officer, President & Chairman | 1M | — |
| Antony A. Riley | Chief Financial Officer | 633.0K | male |
| Barbara K. Finck | Acting Senior Medical Clinician & Director | 600.0K | — |
| Christopher Roenfeldt | Chief Operating Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for FBRX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
